The most important message in today’s Q4 2018 report was that the first European patient has been dosed in the POLAR studies. Recruitment of patients is now ongoing in all regions, strengthening our confidence about the timeline of top-line readout in Q4 2020. Overall, we continue to see great value in the stock.